Search

everythinglearnresearchcommunity

for

Search:↓

A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

The conversation is about expecting results from Breezula, a hair loss treatment, with no new information released as of April 1st. Some joked it's just onion juice, while another comment suggested a conspiracy to cause baldness.

Castor oil's effectiveness for male pattern baldness, receding hairline, and thinning crown is questioned, including its application method and potential side effects. The user also mentions experiencing hair shedding with coconut oil.

A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Topical Dutasteride may halt hair loss and effectively treat androgenic alopecia. Combining low-dose oral Dutasteride with topical application could maximize regrowth and minimize side effects.

A user's 9 month progress using Finasteride, Derma Pen/Roller and Minoxidil to treat hair loss. Replies in the conversation include advice on topical application of Minoxidil and Dutasteride for regrowth and hair thickness.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Microneedling combined with minoxidil and finasteride shows significant hair regrowth, though opinions on its effectiveness vary. Some users report substantial benefits, while others highlight the need for more research and consistency in application.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

The post discusses concerns about the practicality of using Minoxidil foam for hair loss, including the frequency of application, preparation, coverage area, and drying time. Responses suggest that missing a dose isn't detrimental, it can be applied once a day, it works on all hair areas, and it doesn't need to be perfectly dry before application.

The user "RenegadeMountie" shared their progress with topical finasteride and minoxidil for hair loss. They reported consistent use for 3 months, with noticeable improvement in hair thickness and new growth. Other users recommended using hair loss concealers and expressed confidence in seeing more progress in the future.

The conversation is about the potential dangers of taking oral minoxidil and grapefruit juice together. Some users express concern about dangerous drug interactions, while others argue that grapefruit juice may inhibit the metabolism of finasteride. The conclusion is that grapefruit juice may make finasteride less effective, but it won't affect minoxidil.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

A user's success in treating their hair loss with 2x daily topical dutasteride and minoxidil, as well as the potential for using less frequent application of topical dutasteride due to its long half-life.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

A user reported better hair regrowth with 5 mg oral minoxidil and 1 mg dutasteride than with finasteride and topical minoxidil, calling topical minoxidil a scam. Replies varied, with some defending topical minoxidil, questioning the user's application method, and suggesting that previous treatments might be contributing to the observed results.

. This conversation is about a user's progress while using minoxidil and finasteride to treat hair loss, with emphasis on taking oral finasteride at night before bed for optimal results. They also discuss the brand of medication being used (Morr F 5%) and the importance of taking a generic version of the same drug.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

Low-dose oral minoxidil is used for hair loss and does not significantly affect blood pressure but may increase heart rate and cause hypotensive symptoms. Some users experience side effects like palpitations and shortness of breath, while others find it effective; topical minoxidil with tretinoin is also considered.

Topical finasteride is less popular due to inconvenience, cost, and availability, while oral finasteride is favored for ease and safety. Some users experience side effects with topical use, but find it effective with minoxidil, though opinions on its efficacy vary.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.